天演药业公布2026年临床数据公布与研发进展计划

Core Viewpoint - Tianyan Pharmaceutical has announced its business progress and annual goals for 2026, including multiple clinical data releases and research plans [1]. Recent Events - In Q1 2026, the company plans to release updated research data from a 1b/2 phase study of muzastotug (ADG126) combined with pembrolizumab for patients with third-line or higher microsatellite stable colorectal cancer (MSS CRC), including results from the 10 mg/kg dose group (41 patients) and the 20 mg/kg dose group (26 patients) [1]. - Concurrently, the company will share clinical research results in collaboration with Roche, evaluating the efficacy and safety of muzastotug combined with atezolizumab and bevacizumab for first-line treatment of hepatocellular carcinoma (HCC) [1]. - New data will be disclosed, including preliminary data from a new patient cohort using muzastotug combined with pembrolizumab and standard treatment (fruquintinib) for MSS CRC, as well as early progress from a phase 2 trial of neoadjuvant treatment for colorectal cancer led by the National University Hospital of Singapore [1]. Product Development Progress - Patient enrollment is expected to be completed for the randomized phase 2 dose optimization study of muzastotug, which aims to determine the optimal dosing regimen for phase 3 clinical trials [2]. - The company will continue to advance collaboration and licensing agreements, including projects with partners such as Sanofi and Third Arc Bio [2]. Financial Status - As of December 31, 2025, the company reported cash and cash equivalents of $74.5 million (unaudited), which is expected to support operations until the end of 2027, providing funding assurance for the aforementioned plans [3].